Forte Biosciences prices $150M public offering of 5.7M shares at $26.27/share

Forte Biosciences, Inc.

Pricing of 5,709,936 shares at $26.27 per share for gross proceeds of ~$150M.
Underwriters have 30-day option to buy up to 856,490 additional shares.
Offering expected to close April 10, 2026; net proceeds ~$141M.
Proceeds to fund working capital and clinical development of autoimmune product candidate.
Strategic investment from argenx BV noted; Guggenheim and Barclays are joint book-runners.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Forte Biosciences, Inc. entered into Underwriting Agreement with Guggenheim Securities, LLC valued at approximately $150 million (effective 2026-04-08).

Action: entry
Agreement: underwriting
Counterparty: Guggenheim Securities, LLC
Value: approximately $150 million
Effective: 2026-04-08

Exact text from the filing

On April 8, 2026, Forte Biosciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 5,709,936 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $26.27 per share (the “Shares”).

View on SEC.gov

Browse all material agreements →

Forte Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-148796

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.